



**HAL**  
open science

## **Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19**

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, Sophie Six, Caroline Loiez, Frédéric Wallet

### ► **To cite this version:**

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, et al.. Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19. *Emerging Infectious Diseases*, 2020, 26 (8), pp.1939-1941. <10.3201/eid2608.201413>. <hal-02566167>

**HAL Id: hal-02566167**

**<https://hal.science/hal-02566167v1>**

Submitted on 12 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

1 **Running Title :** PVL-secreting *S. aureus* and SARS-CoV-2 coinfection

2 **Keywords :** COVID-19 ; necrotizing pneumonia; Panton-Valentine leukocidin; SARS-CoV-  
3 2; *Staphylococcus aureus*

4 **Title:** Panton-Valentine leukocidin-secreting *Staphylococcus aureus* complicating SARS-  
5 CoV-2 infection : a case report

6 **Authors:** Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent  
7 Robriquet, Sophie Six, Caroline Loïez, Frédéric Wallet

8 **Author affiliations:**

9 CHU Lille, F-59000 Lille, France (C. Duployez, R. Le Guern, C. Tinez, AL. Lejeune, L.  
10 Robriquet, S. Six, C. Loïez, F. Wallet)

11 Univ. Lille, F-59000 Lille, France (C. Duployez, R. Le Guern, AL. Lejeune)

12

13 **Abstract – 42 words**

14 Necrotizing pneumonia induced by Panton-Valentine leukocidin (PVL) secreting  
15 *Staphylococcus aureus* is a rare but life-threatening infection. It has been described following  
16 influenza. We present a fatal case of this superinfection in a young adult infected by Severe  
17 Acute Respiratory Syndrome Coronavirus 2.

18

19 **Text – 678 words**

20 Panton-Valentine leukocidin (PVL) is a cytotoxin produced by some strains of  
21 *Staphylococcus aureus*. These strains are responsible for primary skin infections and  
22 necrotizing pneumonia. This rare entity is mainly described in young immunocompetent  
23 patients with an influenza-like prodrome and has a high lethality rate (1, 2). We report herein  
24 a case of necrotizing pneumonia induced by PVL-secreting methicillin-susceptible *S. aureus*  
25 in a patient infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

26 In March 2020, during SARS-CoV-2 outbreak in France, a man in his thirties without  
27 comorbidities presented at the emergency department with fever, cough, and blood-streaked  
28 sputum developing for 3 days. A diagnosis of pleuropneumonia was made and antimicrobial  
29 therapy was initiated with cefotaxime plus metronidazole. *Streptococcus pneumoniae* and  
30 *Legionella pneumophila* serotype 1 urinary antigens were negative; respiratory viruses  
31 screening PCR was negative. The next day, further respiratory deterioration required his  
32 transfer in Intensive Care Unit (ICU) for intubation, mechanical ventilation, and inotropic  
33 support. Spiramycin was added to the previous probabilistic antibiotic. Chest CT pointed out a  
34 parenchymal consolidation of the left upper lung, without ground-glass opacities commonly  
35 described in Coronavirus Disease 2019 (COVID-19) (3). Four days after intubation, the  
36 patient was not getting better. SARS-CoV-2 RT-PCR was performed on endotracheal  
37 aspirate, using the method developed by the National Reference Centre for respiratory viruses

38 (Institut Pasteur, Paris), and was positive for the pandemic SARS-CoV-2 (4). Another chest  
39 CT showed worsening of bilateral parenchymal damage with complete consolidation of the  
40 left lung, cavitory lesions suggestive of multiple abscesses, and appearance of areas of  
41 ground-glass opacities in the right lung (Figure 1). The chest radiograph also revealed a left  
42 pleural effusion. The bacteriological analysis of pleural drainage revealed the presence of  
43 Gram-positive cocci; the culture yielded a monomicrobial *S. aureus*, identified using MALDI-  
44 TOF spectrometry mass (Bruker Daltonics, Wissembourg, France). The strain was resistant  
45 only to penicillin G (VITEK 2 system, BioMérieux, Marcy l'Etoile, France). Because of this  
46 necrotizing pneumonia associated with acute respiratory distress syndrome, a PVL-producing  
47 strain was suspected. PVL production was confirmed using a specific PCR, as described  
48 previously by Deurenberg et al. (5). Previous antimicrobial therapy was changed into  
49 oxacillin plus clindamycin (for antitoxin effect) against methicillin-susceptible *S. aureus*, and  
50 lopinavir/ritonavir (quickly stopped for suspected toxicity) plus azithromycin against SARS-  
51 CoV-2. Three days later, given a lack of clinical improvement, antimicrobial therapy was  
52 incremented for piperacillin-tazobactam plus linezolid (for antitoxin effect). At the  
53 bronchoscopy, the left bronchial tree was obstructed by purulent secretions. Owing to  
54 deterioration of respiratory, renal and liver functions, venovenous extracorporeal membrane  
55 oxygenation (ECMO) and anticoagulation were initiated ten days after ICU admission. Two  
56 days later, upper left lobectomy was performed, and antimicrobial therapy was incremented  
57 with meropenem, gentamicin plus linezolid. Unfortunately, the patient finally died 17 days  
58 after his admission to the hospital.

59 PVL-secreting *S. aureus* necrotizing pneumonia is frequently preceded by an  
60 influenza-like infection (6), which may be a possible causative factor. Particularly, influenza  
61 virus is known to impede phagocytic killing and damage the bronchial epithelium, thus  
62 reducing secretin clearance and facilitating bacteria adhesion (2). It also induces an influx of

63 immune cells to lung tissues, including neutrophils; the rapid killing of these cells by PVL  
64 and release of the inflammatory mediators may promote disease development by damaging  
65 the epithelium (7, 8). The association of PVL-secreting *S. aureus* and influenza virus has been  
66 previously reported in the literature (6, 9). We report a PVL-secreting *S. aureus*  
67 superinfection in COVID-19. It points out that the new SARS-CoV-2 is, in the same way, a  
68 facilitating factor for PVL-producing *S. aureus* necrotizing pneumonia.

69 In 2003, during SARS-CoV outbreak, an increase in *S. aureus* superinfection (mostly  
70 methicillin-resistant *S. aureus* ventilator-acquired pneumonia) was described. Given common  
71 points between SARS-CoV-2 and previous coronaviruses, Lupia et al. discussed this issue for  
72 COVID-19, suggesting to consider anti-methicillin-resistant *S. aureus* coverage in order to  
73 reduce the risk of superinfection (10).

74 In PVL-producing *S. aureus* superinfection, prescribing antibiotics that have an antitoxin  
75 effect, such as clindamycin or linezolid, remains important (2). Thus, in previously healthy  
76 young adults admitted in ICU for COVID-19 with *S. aureus* superinfection, a PVL-producing  
77 strain should be evocated.

78

## 79 **References**

80 1. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association  
81 between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin  
82 and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet.  
83 2002;359:753-9.

84

85 2. Kreienbuehl L, Charbonney E, Eggimann P. Community-acquired necrotizing  
86 pneumonia due to methicillin-sensitive *Staphylococcus aureus* secreting Panton-

- 87 Valentine leukocidin: a review of case reports. *Ann Intensive Care*. 2011; 1: 52.  
88 doi: 10.1186/2110-5820-1-52  
89
- 90 3. Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19)  
91 Outbreak: What the Department of Radiology Should Know. *J Am Coll Radiol*. 2020  
92 Feb 19. pii: S1546-1440(20)30150-2. doi: 10.1016/j.jacr.2020.02.008.  
93
- 94 4. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al.  
95 First cases of coronavirus disease 2019 (COVID-19) in France: surveillance,  
96 investigations and control measures, January 2020. *Euro Surveill*. 2020 Feb;25(6). doi:  
97 10.2807/1560-7917.ES.2020.25.6.2000094.  
98
- 99 5. Deurenberg RH, Vink C, Driessen C, Bes M, London N, Etienne J, et al. Rapid  
100 detection of Panton-Valentine leukocidin from clinical isolates of *Staphylococcus*  
101 *aureus* strains by real-time PCR. *FEMS Microbiol Lett*. 2004 Nov 15;240(2):225-8.  
102 doi: 10.1016/j.femsle.2004.09.031.  
103
- 104 6. Jacquot A, Luyt CE, Kimmoun A, Levy B, Baux E; Fluvalentine Study group.  
105 Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine  
106 leucocidin positive *Staphylococcus aureus* in intensive care units: a retrospective  
107 nationwide study. *Intensive Care Med*. 2019;45(9):1312–1314. doi:10.1007/s00134-  
108 019-05665-3  
109
- 110 7. Niemann S, Ehrhardt C, Medina E, Warnking K, Tuchscher L, Heitmann V et al.  
111 Combined action of influenza virus and *Staphylococcus aureus* panton-valentine

112 leukocidin provokes severe lung epithelium damage. *J Infect Dis.* 2012;206(7):1138–  
113 1148. doi:10.1093/infdis/jis468

114

115 8. Löffler B, Niemann S, Ehrhardt C, Horn D, Lanckohr C, Lina G et al. Pathogenesis of  
116 *Staphylococcus aureus* necrotizing pneumonia: the role of PVL and an influenza  
117 coinfection. *Expert Rev Anti Infect Ther.* 2013;11(10):1041–1051.  
118 doi:10.1586/14787210.2013.827891

119

120 9. Riedweg-Moreno K, Wallet F, Blazejewski C, Goffard A. Successful management of  
121 Panton-Valentine leukocidine-positive necrotising pneumonia and A/H1N12009  
122 influenzavirus coinfection in adult. *BMJ Case Rep.* 2014;2014:bcr2013201120.  
123 doi:10.1136/bcr-2013-201120

124

125 10. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019  
126 novel coronavirus (2019-nCoV) outbreak: A new challenge. 2020 Mar. *J Glob*  
127 *Antimicrob Resist.* 2020;21:22–27. doi:10.1016/j.jgar.2020.02.021.

128

129 Address for correspondence : Claire Duployez, Laboratoire de Bactériologie - Institut de  
130 Microbiologie, Centre de Biologie Pathologie, F-59037 – Lille CEDEX, France ; email :  
131 claire.duployez@chru-lille.fr; Telephone number: +33 3.20.44.54.80 ; Fax number: +33  
132 3.20.44.48.95